Comparison of the predictive efficacy of pleural fluid CEA, serum CEA and pleural fluid CEA/serum CEA combined with pleural fluid CEA for EGFR mutations in patients with lung adenocarcinoma with MPE. The gene discussed is CEACAM5; the disease is lung adenocarcinoma.